Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00923832 · ClinicalTrials.gov registry record
Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis
A clinical trial of Invasive Pulmonary Aspergillosis and Immunocompromised Host, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 2
- Study locations
NCT00923832: Completed study of Invasive Pulmonary Aspergillosis and Immunocompromised Host, sponsored by National Cancer Institute (NCI).
NCT00923832 is a study of Invasive Pulmonary Aspergillosis and Immunocompromised Host that has completed, run by National Cancer Institute (NCI). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00923832, a study of Invasive Pulmonary Aspergillosis and Immunocompromised Host, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 2
- Study locations
Study Summary
Background: * Fungal infections of the lung (pneumonia) can be caused by molds, such as Aspergillus and Zygomycetes, but these causes are often difficult for a doctor to diagnose. Early and accurate diagnosis of these infections can help doctors to select the correct medicines for proper treatment. * A number of methods are used to diagnose fungal pneumonia. Ones that are commonly used in clinical practice include radiographic imaging (chest X-rays and computed tomography (CT) scans), blood tests, and cultures taken from fluid from the lungs (broncho-alveolar lavage (BAL) fluid). Other new methods may improve the diagnosis of fungal pneumonias. These methods include tests that can detect DNA from the fungal germ in blood and BAL fluid of some patients with these infections. Objectives: * To help develop better and more accurate methods of diagnosing fungal lung infections. * To detect fungal DNA and chemicals in the bloodstream and BAL fluid of immunocompromised patients with pneumonia. Eligibility: \- Immunocompromised patients who are currently enrolled in another NIH protocol and who have a CT scan that shows a possible fungal infection of the lung. Design: * Researchers will review patients' existing medical records and CT scans, and current pneumonia treatment plans. * Patients will provide blood and BAL samples for the duration of their treatment for pneumonia, as required by researchers. Additional CT scans will not be performed, except as part of existing treatment plans.
Conditions Studied
Study Locations (2)
District of Columbia
- Childrens National Medical Center - Washington D.C.
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Start Date | 2009-03-30 |
| Est. Completion | 2009-11-23 |
What the finished NCT00923832 record still lists
NCT00923832 is an observational study that tracks outcomes without assigning an intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 4 conditions, with Invasive Pulmonary Aspergillosis appearing as the primary indexed condition, and to 0 interventions.
NCT00923832 reports a single indexed study location in District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT00923832 about?
NCT00923832 is a clinical study titled "Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis". Background: * Fungal infections of the lung (pneumonia) can be caused by molds, such as Aspergillus and Zygomycetes, but these causes are often difficult for a doctor to diagnose. Early and accurate diagnosis of these infections can help doctors to select the correct medicines for proper treatment....
What is the current status of trial NCT00923832?
This trial is currently completed. The study started on 2009-03-30. Estimated completion is 2009-11-23.
What conditions does trial NCT00923832 study?
This clinical trial studies the following conditions: Invasive Pulmonary Aspergillosis, Immunocompromised Host, Invasive Pulmonary Fungal Infection, Invasive Pulmonary Zygomycosis.
Who is sponsoring clinical trial NCT00923832?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00923832 being conducted?
This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Pulmonary Aspergillosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI